HK Stock Market Move | LIVZON PHARMA (01513) saw a nearly 4% increase in the final trading session. The application for the market approval of Lai Kang Qita Monoclonal Antibody Injection has been accepted.

LIVZON PHARMA (01513) rose nearly 4% at the close, and as of the time of writing, it had risen 3.62% to 26.34 Hong Kong dollars, with a trading volume of 18.49 million Hong Kong dollars. On the news front, Livzon Pharmaceutical Group Inc. recently announced that its Class 1 innovative biologic drug Leconkitamab Monoclonal Antibody, used to treat ankylosing spondylitis, has had its market application officially accepted by the National Medical Products Administration. This is the second NDA acceptance for the drug, following the acceptance of the market application for the indication of psoriasis and its inclusion in priority review. Public information shows that Leconkitamab Monoclonal Antibody is the first domestically developed IL-17A/F dual antibody in China. With the gradual approval of additional indications in the future, Leconkitamab Monoclonal Antibody will further enrich LIVZON PHARMA's product portfolio in the field of autoimmune diseases, enhancing the company's competitiveness in the global biopharmaceutical market.